ATR-IN-23 

ATR-IN-23 (Compound 34) is a potent and selective ATR inhibitor with an IC₅₀ of 1.5 nM. ATR-IN-23 has potent antiproliferative effects on LoVo cells and synthetic lethality on HT-29 cells, and can be used in the study of DNA damage response (DDR)-deficient cancers^[1].

ATR-IN-23 possesses significant inhibitory potency against ATR, with an IC₅₀ value of 1.5 nM, and displays strong antiproliferative activities against LoVo cells, with an IC₅₀ value of 0.073 μM^[1].
ATR-IN-23 exhibits moderate antiproliferative potency against HT-29 cells with an IC₅₀ value of 0.161 μM^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

ATR-IN-23 shows acute toxicity at a maximum concentration of 2000 mg/kg and possesses moderate safety in ICR mice^[1].
ATR-IN-23 (50 mg/kg; once a day or twice a day; p.o.; 21 days) exhibits moderate antitumor efficacy in BALB/c nude mice^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

458.56

C₂₀H₂₂N₆O₃S₂

2923800-62-6

CNC1=NC2=C(N1C3=NC4=C(C(N5CCOC[C@H]5C)=N3)SC=C4S(C)(=O)=O)C=CC=C2

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Duan Y, et al. Discovery of Thieno[3,2-d]pyrimidine derivatives as potent and selective inhibitors of ataxia telangiectasia mutated and Rad3 related (ATR) kinase. Eur J Med Chem. 2023 Jul 5;255:115370.  [Content Brief]